American Journal of Obstetrics & Gynecology
Volume 200, Issue 2 , Pages 170.e1-170.e7 , February 2009

Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy

  • Karel Allegaert, PhD

      Affiliations

    • Division of Woman and Child, University Hospitals Leuven, Leuven, Belgium
    • Corresponding Author InformationReprints: Karel Allegaert, PhD, Neonatal Intensive Care Unit, Department of Woman and Child, University Hospital, Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    • ,
  • Tim van Mieghem, MD

      Affiliations

    • Division of Woman and Child, University Hospitals Leuven, Leuven, Belgium
    • ,
  • Rene Verbesselt, PhD

      Affiliations

    • Center for Clinical Pharmacology, University Hospitals Leuven, Leuven, Belgium
    • ,
  • Jan de Hoon, PhD

      Affiliations

    • Center for Clinical Pharmacology, University Hospitals Leuven, Leuven, Belgium
    • ,
  • Maissa Rayyan, MD

      Affiliations

    • Division of Woman and Child, University Hospitals Leuven, Leuven, Belgium
    • ,
  • Roland Devlieger, PhD

      Affiliations

    • Division of Woman and Child, University Hospitals Leuven, Leuven, Belgium
    • ,
  • Jan Deprest, PhD

      Affiliations

    • Division of Woman and Child, University Hospitals Leuven, Leuven, Belgium
    • ,
  • Brian J. Anderson, PhD

      Affiliations

    • Department of Anesthesiology, University of Auckland, Auckland, New Zealand

Received 25 March 2008 ,Revised 11 July 2008 ,Accepted 29 August 2008.

References 

  1. Gyssens IC. Preventing postoperative infections: current treatment recommendations. Drugs. 1999;57:175–185
  2. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease: revised guidelines from CDC. MMWR Recomm Rep. 2002;51(RR-11):1–22
  3. Vella-Brincat JW, Begg EJ, Kirkpatrick CM, Zhang M, Chambers ST, Gallangher K. Protein binding of cefazolin is saturable in vivo both between and within patients. Br J Clin Pharmacol. 2007;63:753–757
  4. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet. 2005;44:989–1008
  5. Philipson A, Stiernstedt G, Ehrnebo M. Comparison of the pharmacokinetics of cephradine and cefazolin in pregnant and non-pregnant women. Clin Pharmacokinet. 1987;12:136–144
  6. Popovic J, Grujic Z, Sabo A. Influence of pregnancy on ceftriaxone, cefazolin and gentamicin pharmacokinetics in caesarean vs. non-pregnant sectioned women. J Clin Pharm Ther. 2007;32:595–602
  7. Pacifici GM. Placental transfer of antibiotics administered to the mother: a review. Int J Clin Pharmacol Ther. 2006;44:57–63
  8. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr. 2006;165:819–829
  9. Brown CE, Christmas JT, Bawdon RE. Placental transfer of cefazolin and piperacillin in pregnancies remote from term complicated by Rh isoimmunization. Am J Obstet Gynecol. 1990;163:938–943
  10. Fiore Mitchell T, Pearlman MD, Chapman RL, Bhatt-Mehta V, Faix RG. Maternal and transplacental pharmacokinetics of cefazolin. Obstet Gynaecol. 2001;98:1075–1079
  11. Deprest J, Jani J, Lewi L, et al. Fetoscopic surgery: encouraged by clinical experience and boosted by instrument innovation. Semin Fetal Neonatal Med. 2006;11:398–412
  12. Deprest J, Jani J, Gratacos E, et al. Fetal intervention for congenital diaphragmatic hernia: the European experience. Semin Perinatol. 2005;29:94–103
  13. Lewi L, Van Schoubroeck D, Gratacos E, Witters I, Timmerman D, Deprest J. Monochorionic diamniotic twins: complications and management options. Curr Opin Obstet Gynecol. 2003;15:177–194
  14. Duffull SB, Kirkpatrick CM, Green B, Holford NH. Analysis of population pharmacokinetic data using NONMEM and WinBUGS. J Biopharm Stat. 2005;15:53–73
  15. Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Statistical Science. 1986;1:54–77
  16. Rattie ES, Ravin LJ. Pharmacokinetic interpretation of blood levels and urinary excretion data for cefazolin and cephalothin after intravenous and intramuscular administration in humans. Antimicrob Agents Chemother. 1975;7:606–613
  17. Andrew MA, Easterling TR, Carr DB, et al. Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clin Pharmacol Ther. 2007;81:547–556
  18. Muller AE, Dejongh J, Oostvogel PM, et al. Amoxicillin pharmacokinetics in pregnant women with preterm premature rupture of the membranes. Am J Obstet Gynecol. 2008;198:108.e1–108.e6
  19. Ci L, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Involvement of MRP4 (ABCC4) in the luminal efflux of ceftizoxime and cefazolin in the kidney. Mol Pharmacol. 2007;71:1591–1597
  20. Uwai Y, Saito H, Inui K. Rat renal organic anion transporter rOAT1 mediates transport of urinary-excreted cephalosporins, but not of biliary-excreted cefoperazone. Drug Metab Pharmacokinet. 2002;17:125–129
  21. Bernard B, Barton L, Abate M, Ballard CA. Maternal-fetal transfer of cefazolin in the first twenty weeks of pregnancy. J Infect Dis. 1977;136:377–382
  22. Fellinger EK, Leavitt BJ, Hebert JC. Serum levels of prophylactic cefazolin during cardiopulmonary bypass surgery. Ann Thorac Surg. 2002;74:1187–1190
  23. Arkaravichien W, Tamungklang J, Arkaravichien T. Cefazolin induced seizures in hemodialysis patients. J Med Assoc Thai. 2006;89:1981–1983
  24. Nau H. Clinical pharmacokinetics in pregnancy and perinatology: II, penicillins. Dev Pharmacol Ther. 1987;10:174–198
  25. Gomez R, Romero R, Nien JK, et al. Antibiotic administration to patients with preterm premature rupture of membranes does not eradicate intra-amniotic infection. J Matern Fetal Neonatal Med. 2007;20:167–173
  26. Zajicek A, Giacoia GP. Obstetric clinical pharmacology: coming of age. Clin Pharmacol Ther. 2007;81:481–482

 Cite this article as: Allegaert K, van Mieghem T, Verbesselt R, et al. Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy. Am J Obstet Gynecol 2009;200:170.e1-170.e7.

 Drs Allegaert and Deprest are supported by the Fonds Wetenschappelijk Onderzoek-Vlaanderen. Dr Devlieger is supported by the Clinical Research Fund of the University Hospitals, Leuven. Dr van Mieghem is supported by a Grant of the EC (EuroSTEC, LSHC-CT-2006-037409).

PII: S0002-9378(08)01036-3

doi: 10.1016/j.ajog.2008.08.067

American Journal of Obstetrics & Gynecology
Volume 200, Issue 2 , Pages 170.e1-170.e7 , February 2009

Article Tools

* Image Usage & Resolution